ป้ายกำกับ: with
Eisai’s Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures
TOKYO, Aug 2, 2021 – […]
TheCapitalNet appoints Privity FZ LLE to expand MENA footprint
DUBAI, UAE, Aug 2, 2021 & […]
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)
TOKYO, Jul 30, 2021 ̵ […]
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
TOKYO, Jul 30, 2021 ̵ […]
DigiMax Continues Global Marketing Expansion into Asia with Signing of Collaboration Deal in Korea
TORONTO, ON / ACCESSWIRE, […]
Moonstake Integrates Muse Finance for MUSE Lockdrop and Advanced DeFi Connectivity
SINGAPORE, Jul 28, 2021 & […]
Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
TOKYO, Jul 27, 2021 ̵ […]
NFT Collectible “God Temple” Launches Public Sale, Introduces Play-to-Earn Game Model with Comic Artist Pat Lee’s Artwork
HONG KONG, Jul 26, 2021 & […]
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
TOKYO and KENILWORTH, N.J […]